1 / 20

Genetic manipulation of donor T cells to control Graft versus Host disease (GvHD)

Genetic manipulation of donor T cells to control Graft versus Host disease (GvHD). Jordan Laboratory for hemato-oncology Hematology Department Eric Lammertsma - Tineke Lenstra - Hiljanne van der Meer Tom van Meerten – Samantha Hol. Contents. Introduction Approach Methods Conclusions

fauve
Download Presentation

Genetic manipulation of donor T cells to control Graft versus Host disease (GvHD)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Genetic manipulation of donor T cells to control Graft versus Host disease (GvHD) Jordan Laboratory for hemato-oncology Hematology Department Eric Lammertsma - Tineke Lenstra - Hiljanne van der Meer Tom van Meerten – Samantha Hol

  2. Contents • Introduction • Approach • Methods • Conclusions • Discussion

  3. Introduction • Haematological malignancies -> Stem Cell Transplantation -> Complication: Graft versus Host Disease

  4. Role of donor T-cells in SCT

  5. Treatment of GvHD • Immunosuppressive drugs • Suicide gene therapy: • HSV-thymidine kinase with ganciclovir

  6. Suicide gene therapy: CD20/αCD20 • Transduce T-cells with CD20-gene • Transplant • T-cell depleted Hematopoeitic Stem Cells • CD20 T-cells • GvHD -> αCD20 = Rituximab

  7. Suicide gene therapy: CD20/αCD20 Rituximab (CD20 antibody) + complement

  8. FACS SS SS FS FS Side Scatter (SSC) Side Scatter (SSC) Forward Scatter (FSC) Forward Scatter (FSC)

  9. Approach • Transfect Ph-ampho cells to produce virus with CD20 vector • Transduce CD20 DNA to human CEM cells • Examine the expression of CD20 • Examine the effect of Rituximab on transduced cells

  10. Transfection • Ph-ampho cells for virus production • Gene variants: • CD20 • CD20 wpre ic • CD20 wpre • CD20 ins9

  11. Transfection • CD20, CD20 wpre ic and CD20 wpre transfected • CD20 ins9 not expressed • Virus harvested

  12. Transduction • CEM cells (human donor T cells) • Incubated with 4 virus concentrations • Examined CD20 expression (transduction efficiency)

  13. Transduction • CD20 expression in transduced T cells

  14. Transduction

  15. Effect of Rituximab Rituximab (CD20 antibody) + complement

  16. Effect of Rituximab Clones Control

  17. Conclusions • CD20 T-cell production possible • Rituximab causes cell lysis -> independent of level of CD20 expression

  18. Discussion • No reliable negative control • Up to 10% CD20 T-cell survival • Rituximab specific for CD20 (?) • CD20 on human B-cells

More Related